Insights

Zolgensma and Drug Development in the Era of One-and-Done

Four Calls-to-Action for Digital Disrupters from #RHSUM19

DeciBio News

DeciBio News: Introducing new partner, Andrew Aijian, PhD

DeciBio News

DeciBio News: Employee Benefits Update

DeciBio News

DeciBio News: DeciBio spins off technology products as subsidiary entity "DeciBio Analytics"

Highly-Multiplexed Tissue Imaging: The Research Tool of The Future

I/O Biomarker Spotlight: Digital Pathology and Multiplex Spatial Tissue Analysis

An Updated Look at TMB: What Has Changed and What to Expect

AACR 2019: DeciBio Highlights

AGBT 2019: Spatial Profiling Among Many Growth Applications in Genomics

Lessons Learned from the World's First Gene-Edited Babies

Three lessons for digital health entrepreneurs from #RHSUM18

The Implications and Benefits of Early Identification of Alzheimer’s Disease

ASHG 2018: DeciBio Highlights

Guardant Health stock soars after IPO, Lexent Bio joins the serial monitoring gold rush and a UK research team develops a novel cfDNA assay

Blockchain in Healthcare: Today and Tomorrow

AGBT Precision Health 2018 Highlights: Precision Medicine Builds Up Steam Outside Academia

From Trial to Drug Label: Identifying the Next Wave of Oncology Biomarkers

New CRISPR Companies Heat Up as Skepticism Grows

Exploring Collaboration Networks within Liquid Biopsy Research

Think Twice Before Divesting CRISPR Amid Cancer Concerns

CRISPRcon 2018 Highlights

ASCO 2018 Summary Highlights

Liquid Biopsy Trends to Watch at ASCO 2018

AACR 2018 Summary Highlights

DeciBio Q&A

What Are the Different Career Paths for Life Sciences Graduates?

Liquid Biopsy Updates: Oncotype SEQ Drops Out, ASCO / CAP Release Joint Report, NCD Bodes Well for Some

The Rise of Tumor Mutation Burden in Immuno-Oncology

Time-Out: Talking Strategy for CRISPR’s Big 3

Oncology Clinical Trial Timeline

Current Liquid Biopsy Trends

Highlights from AGBT 2018

2018 Trends to Watch in Clinical Diagnostics, Research Tools, and Health Technology

3 Questions to Ask Yourself to Ensure a Sound Business Case

5 Insights from Our New Clinical NGS Database

Next-Gen Cancer Immunotherapy Biomarkers: Implications for Research Tools and Clinical Diagnostics

Using Design Sprints for Life Science Market Research

Tempus O launches, F1CDx gains approval and Grail appoints a new CEO

November 2017 Liquid Biopsy News Highlights

Visualizing AGBT Precision Health Abstracts

October 2017 Liquid Biopsy News Highlights

#RHSUM 2017 Takeaways

Mission Bio Launches Single-Cell DNA Analysis Platform at ASHG 2017

DeciBio Culture Focus: Women in Consulting

The Rise of AI and Analytics as Clinical Decision Support Tools

Transitioning Novel Research Tools into Clinical Diagnostics

Pioneering Health Intelligence: An Interview with Dr. Ashley Van Zeeland (CTO, Human Longevity)

Life Science Research: 4 Technologies Poised to Drive Proteomics Forward

Immuno-Oncology Biomarkers: Landscape Summary 2017

Hype or Bust: How Exciting is Your Novel Technology?

Immuno-Oncology Biomarker of the Week

NGS Manufacturer Market to Face Headwinds

Life Science Research Tools Market Growth Driven by Biopharma and Applied Markets

Poll: What does the future look like for single cell genomics?

Tempus generates chatter at #ASCO2017

ASCO Musings: Diagnostics and Research Tools Takeaways from ASCO17

Competitors Jostle for Share as Fluidigm Signals Deprioritization of Single-Cell Genomics

Talking Healthcare Analytics with Wout Brusselaers, CEO of Deep 6 AI

AGBT 2017: DeciBio Highlights

NanoString poised to make a play in clinical sequencing with Hyb & Seq

Illumina, Bio-Rad, and 10X Genomics look to take advantage of the market that Fluidigm built

Diagnostic Biomarkers for Cancer Immunotherapy – Updated Jan. 2017

The Microbiome: What’s All the Hype About?

Oxford Nanopore Reaches an Inflection Point

Cancer Immunotherapy – Review of a Breakout Year and What to Expect for 2017

AGBT Precision Health 2016: DeciBio Poster Details

Three Reasons Why Alphabet (Google) Can Dominate Healthcare

2016 Immuno-Oncology Summit Takeaways – Immuno-Oncology Biomarkers 2.0

Clinical Use of Next Generation Sequencing on the Rise

DeciBio's Recipe for Success

Diagnostic Biomarkers for Cancer Immunotherapy – Moving Beyond PD-L1

IBM Watson Health Pushes Further into Healthcare with Machine Learning

An Apple A Day Keeps The Doctor Away (But Still In The Loop)

AGBT 2016: DeciBio Highlights

Illumina Bio-Rad and 10X Genomics Update

With the GeneReader Launch, Qiagen Offers a True End-to-End Clinical NGS Solution

Updated DeciBio NGS Report (November 2015)

Single-Cell Genomics: Are we in the Midst of a Market Slowdown?

BD to acquire SCG start-up Cellular Research

Inaugural Issue of “The Journal of Precision Medicine” Released

How a century-old technique is transforming the $6B cell-based assay market

Mark Cuban’s Misguided Healthcare Advice in a Data-Driven World

Theranos One Step Closer to Consumerizing Health

AGBT 2015: Highlights of Another Great Year

10X Genomics Launches GemCode

The Six Million Dollar Man could soon cost a fraction of that

AGBT 2015 Rumors

EnteroMedic’s Maestro System has the potential to unlock the neuromodulation obesity market

Theranos: Catalyzing Healthcare Consumerization

ASHG Exhibitors Open the Kimono

Could stem cells cure diabetes?

Mindshare of Next Generation Sequencing Companies

Illumina's Next Generation Sequencing in the Clinic

DeciBio's Theranos Coverage Featured in the San Jose Mercury News

NGS and dPCR drive growth of the genomics market

Theranos Expands Operations in AZ

DeciBio’s Life Sciences Research Tools Report Update

DeciBio Perspective on Theranos Featured in USA Today

Theranos: Small Sample, Big Opportunity

Roche acquires nanopore sequencing firm Genia